Hormonal
GLP-1 and GIP/GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) and emerging triple agonists (e.g., retatrutide) significantly reduce body weight, improve glycemic control, and reverse hepatic steatosis in patients with obesity and type 2 diabetes.
GLP-1 and GIP/GLP-1 agonists (like semaglutide and tirzepatide) are highly effective for weight loss and reversing liver fat in people with obesity and diabetes. They work by mimicking gut hormones to reduce appetite and improve insulin sensitivity. Triple agonists (like retatrutide) are showing even greater promise for liver fat normalization.
Tirzepatide... has demonstrated significant results in weight reduction and glucose control... SURPASS-3 MRI study... demonstrated meaningful reductions in liver fat content... retatrutide... normalization of fat levels in the liver after 48 weeks of treatment on the highest dose
Why this rating
Supported by Phase 3 RCTs (SURMOUNT-1, SURPASS-3) and Phase 2 trials (Retatrutide).
Source
Potential Therapeutic Targets in Obesity, Sleep Apnea, Diabetes, and Fatty Liver Disease
Christina Gu et al. · Journal of Clinical Medicine · 2024
DOI 10.3390/jcm13082231
More from this paper
- Bariatric surgery (specifically sleeve gastrectomy and Roux-en-Y gastric bypass) achieves sustained weight loss and high rates of type 2 diabetes remission, while also significantly improving or resolving obstructive sleep apnea and metabolic dysfunction-associated steatotic liver disease (MASLD).Good
- Obstructive Sleep Apnea (OSA) is an independent risk factor for the development of Type 2 Diabetes (T2DM) and MASLD, primarily through mechanisms of intermittent hypoxia, sympathetic hyperactivity, and inflammation, rather than solely through obesity.Moderate
- Continuous Positive Airway Pressure (CPAP) therapy has mixed and often limited effects on improving glycemic control (A1c, fasting glucose) and liver fat content in patients with OSA, T2DM, and MASLD, despite reducing sympathetic activity.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →